Takeda Pharmaceutical Company Limited Stock

Equities

4502

JP3463000004

Pharmaceuticals

Delayed Japan Exchange 20:24:37 2024-05-09 EDT 5-day change 1st Jan Change
4,097 JPY +0.66% Intraday chart for Takeda Pharmaceutical Company Limited -0.73% +1.01%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 4,264B 27.41B 37.49B Sales 2025 * 4,028B 25.89B 35.42B Capitalization 6,386B 41.05B 56.14B
Net income 2024 144B 926M 1.27B Net income 2025 * 157B 1.01B 1.38B EV / Sales 2024 1.54 x
Net Debt 2024 * 3,771B 24.24B 33.15B Net Debt 2025 * 3,994B 25.67B 35.11B EV / Sales 2025 * 2.58 x
P/E ratio 2024
45.4 x
P/E ratio 2025 *
38.3 x
Employees 49,095
Yield 2024 *
4.62%
Yield 2025 *
4.67%
Free-Float 99.12%
More Fundamentals * Assessed data
Dynamic Chart
Health Care Climbs as Obesity-Drug Optimism Returns - Health Care Roundup DJ
Sector Update: Health Care Stocks Steady Pre-Bell Thursday MT
Takeda Pharmaceutical's Fiscal Q1 Core Earnings Decline, Revenue Increases; Fiscal 2024 Outlook Issued MT
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss -- Update DJ
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss DJ
Japan's Takeda Pharma says full-year profit slumps 56% RE
Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon CI
Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Full Year of 2024 CI
Takeda Pharmaceutical Company Limited Declares Dividend for the Year Ended March 31, 2024, Payable June 27, 2024; Provides Dividend Guidance for the Second Quarter-End and Year-End of Fiscal Year Ending March 31, 2025 CI
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion RE
EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug MT
Hutchmed notes CHMP's positive opinion for fruiquintinib approval AN
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer MT
Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer CI
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs MT
More news

Latest transcript on Takeda Pharmaceutical Company Limited

1 day+0.61%
1 week-0.73%
Current month-1.40%
1 month-1.70%
3 months-3.85%
6 months-1.49%
Current year+1.01%
More quotes
1 week
4 018.00
Extreme 4018
4 112.00
1 month
4 018.00
Extreme 4018
4 181.00
Current year
4 018.00
Extreme 4018
4 494.00
1 year
3 900.00
Extreme 3900
4 873.00
3 years
2 993.00
Extreme 2993
4 873.00
5 years
2 894.50
Extreme 2894.5
4 873.00
10 years
2 894.50
Extreme 2894.5
6 693.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 14-03-31
Chief Tech/Sci/R&D Officer 45 22-01-31
Compliance Officer 54 11-12-31
Members of the board TitleAgeSince
Director/Board Member 71 16-05-31
Director/Board Member 62 18-12-31
Director/Board Member 71 18-12-31
More insiders
Date Price Change Volume
24-05-09 4,098 +0.69% 1 980 600
24-05-09 4,070 +0.42% 3,465,100
24-05-08 4,053 -1.12% 5,332,100
24-05-07 4,099 -0.63% 6,576,000
24-05-02 4,125 -0.43% 3,157,000

Delayed Quote Japan Exchange, May 09, 2024 at 08:24 pm

More quotes
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,070 JPY
Average target price
4,779 JPY
Spread / Average Target
+17.42%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW